Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2

Abstract Introduction Psoriasis may increase risk for comorbid diabetes and obesity. Tildrakizumab, an anti-interleukin-23 monoclonal antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis, was evaluated in the pivotal phase 3 trials reSURFACE 1 and reSURFACE 2. This...

全面介紹

書目詳細資料

Principais autores:	Jerry Bagel, Ranga Gogineni, Asif Shaikh, Mark G. Lebwohl
格式:	Artigo
語言:	Inglês
出版:	Adis, Springer Healthcare 2026-03-01
叢編:	Dermatology and Therapy
主題:	Psoriasis Diabetes mellitus Obesity Tildrakizumab Interleukin inhibitors Interleukin-23
在線閱讀:	https://doi.org/10.1007/s13555-026-01708-y
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!